行气止痛汤预防食管癌放疗后急性放射性食管炎的有效性观察:单中心双盲随机对照试验方案

注册号:

Registration number:

ChiCTR2100043978 

最近更新日期:

Date of Last Refreshed on:

2021-07-11 18:17:19 

注册时间:

Date of Registration:

2021-03-06 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

行气止痛汤预防食管癌放疗后急性放射性食管炎的有效性观察:单中心双盲随机对照试验方案

Public title:

Chinese Herbal Formula Xingqi Zhitong for Acute Radiation-Induced Esophagitis in Esophageal Cancer: Study Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

行气止痛汤预防食管癌放疗后急性放射性食管炎的有效性观察:单中心双盲随机对照试验方案

Scientific title:

Chinese Herbal Formula Xingqi Zhitong for Acute Radiation-Induced Esophagitis in Esophageal Cancer: Study Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiMCTR2100004535

申请注册联系人:

薛念慈 

研究负责人:

王晞星 

Applicant:

Nianci Xue 

Study leader:

Xixing Wang 

申请注册联系人电话:

Applicant telephone:

+86 16620157521

研究负责人电话:

Study leader's
telephone:

+86 13623618679

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

792769355@qq.com

研究负责人电子邮件:

Study leader's E-mail:

ggyy572216@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广州市越秀区大德路111号

研究负责人通讯地址:

山西省太原市并州西街与青年路交叉路口

Applicant address:

111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China

Study leader's address:

The intersection of Bingzhou West Street and Qingnian Road, Taiyuan City, Shanxi Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州中医药大学第二附属医院(广东省中医院)

Applicant's institution:

Second Clinical Medical College (Second Affiliated Hospital), Guangzhou University of Chinese Medicine

研究负责人所在单位:

山西省中医药研究院

Affiliation of the Leader:

Shanxi Institute of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

szyly2021ky-0101

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

山西省中医药研究院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Shanxi Institute of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2021-01-25 00:00:00

伦理委员会联系人:

郝淑兰

Contact Name of the ethic committee:

Hao Shulan

伦理委员会联系地址:

山西省太原市并州西街与青年路交叉路口

Contact Address of the ethic committee:

The intersection of Bingzhou West Street and Qingnian Road, Taiyuan, Shanxi

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 13834156416

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山西省中医院

Primary sponsor:

Shanxi Provincial Hospital of Chinese Medicine

研究实施负责(组长)单位地址:

山西省太原市并州西街与青年路交叉路口

Primary sponsor's address:

The intersection of Bingzhou West Street and Qingnian Road, Taiyuan, Shanxi

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山西

市(区县):

太原

Country:

China

Province:

Shanxi

City:

Taiyuan

单位(医院):

山西省中医院

具体地址:

并州西街与青年路交叉路口

Institution
hospital:

Shanxi Provincial Hospital of Chinese Medicine

Address:

The intersection of Bingzhou West Street and Qingnian Road

经费或物资来源:

中华人民共和国科技部

Source(s) of funding:

Ministry of Science and Technology, PRC

研究疾病:

急性放射性食管炎  

Target disease:

acute radiation-induced esophagitis

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1、评估行气止痛汤预防食管癌放疗后急性放射性食管炎的疗效; 2、利用唾液蛋白质组学监测行气止痛汤预防食管癌放疗后急性放射性食管炎患者的唾液蛋白的变化规律,寻找治疗过程中疾病的发展、变化及转归的唾液蛋白生物标志物。  

Objectives of Study:

1. To evaluate the efficacy of Xingqi Zhitong Decoction in preventing acute radiation esophagitis after radiotherapy for esophageal cancer; 2. Salivary proteomics was used to monitor the variation of salivary protein in patients with acute radiotherapy esophagitis after Xingqi Zhitong Decoction was used to prevent esophageal cancer, and to search for salivary protein biomarkers for the development, change and outcome of the disease during the treatment process.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

① 完全性食管梗阻、食管深溃疡、食管穿孔或呕血者;
② 在基线前28天有手术史;
③ 30天内参与其他介入临床试验;
④ 妊娠及哺乳期妇女;
⑤ 有严重心、肺、肝、肾功能异常、免疫缺陷者;
⑥ 有不可控的精神类疾病、肿瘤转移性疾病者(根据AJCC第8版M1b);
⑦ 研究者认为该患者不适合进行临床试验的任何其他条件。

Exclusion criteria:

1. Complete esophageal obstruction, deep esophageal ulcer, esophageal perforation or vomiting of blood.
2. History of surgery within 28 days prior to baseline.
3. Participation in other interventional clinical trials within 30 days.
4. Pregnant and lactating women.
5. Those with severe cardiac, pulmonary, hepatic, or renal abnormalities, or immunodeficiency.
6. Those with uncontrollable psychiatric disorders, tumor metastatic disease (according to the AJCC 8th edition M1b).
7. Any other condition that the investigator deems the patient unsuitable for the clinical trial.

研究实施时间:

Study execute time:

From 2021-03-01 00:00:00 To 2023-02-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-03-01 00:00:00 To 2022-08-01 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

45

Group:

Experimental group

Sample size:

干预措施:

服用行气止痛汤

干预措施代码:

Intervention:

Xingqi Zhitong Decoction Granules

Intervention code:

组别:

对照组

样本量:

45

Group:

control group

Sample size:

干预措施:

安慰剂

干预措施代码:

Intervention:

placebo

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山西 

市(区县):

太原 

Country:

China

Province:

Shanxi

City:

Taiyuan

单位(医院):

山西省中医院 

单位级别:

三级中医(综合)医院 

Institution
hospital:

Shanxi Provincial Hospital of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

急性放射性食管炎的发生率

指标类型:

主要指标

Outcome:

Incidence of acute radiation esophagitis

Type:

Primary indicator

测量时间点:

干预期间每周测量,随访期间每月测量

测量方法:

临床医生根据放射性食管炎症状及分级标准测量

Measure time point of outcome:

Measured weekly during the intervention and monthly during the follow-up

Measure method:

The clinician measured the inflammation of the esophagus according to radiation and grading criteria

指标中文名:

急性放射性食管炎临床分级

指标类型:

主要指标

Outcome:

Clinical classification of acute radiation esophagitis

Type:

Primary indicator

测量时间点:

干预期间每周测量,随访期间每月测量

测量方法:

根据放射性食管炎临床分级量表

Measure time point of outcome:

Measured weekly during the intervention and monthly during the follow-up

Measure method:

According to the clinical grading scale of radiation esophagitis

指标中文名:

急性放射性食管炎的发生时间、持续时间

指标类型:

次要指标

Outcome:

The occurrence time and duration of acute radiation esophagitis

Type:

Secondary indicator

测量时间点:

干预期间每周测量,随访期间每月测量

测量方法:

临床医生根据诊断标准决定

Measure time point of outcome:

Measured weekly during the intervention and monthly during the follow-up

Measure method:

The clinician decides based on the diagnostic criteria

指标中文名:

疼痛指数

指标类型:

次要指标

Outcome:

Pain index

Type:

Secondary indicator

测量时间点:

干预期间每周测量,随访期间每月测量

测量方法:

量表测量

Measure time point of outcome:

Measured weekly during the intervention and monthly during the follow-up

Measure method:

Scale for measuring

指标中文名:

吞咽困难

指标类型:

次要指标

Outcome:

Dysphagia

Type:

Secondary indicator

测量时间点:

干预期间每周测量,随访期间每月测量

测量方法:

量表测量

Measure time point of outcome:

Measured weekly during the intervention and monthly during the follow-up

Measure method:

Scale for measuring

指标中文名:

生活质量评分(QOL-C30)

指标类型:

次要指标

Outcome:

Quality of Life Score (QOL-C30)

Type:

Secondary indicator

测量时间点:

干预期间每周测量,随访期间每月测量

测量方法:

量表测量

Measure time point of outcome:

Measured weekly during the intervention and monthly during the follow-up

Measure method:

Scale for measuring

指标中文名:

胃镜检查

指标类型:

附加指标

Outcome:

gastroscopy

Type:

Additional indicator

测量时间点:

干预期间每周测量,随访期间每月测量

测量方法:

胃食管镜检查

Measure time point of outcome:

Measured weekly during the intervention and monthly during the follow-up

Measure method:

Gastroesophageal endoscopy

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

唾液

组织:

Sample Name:

Saliva

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

参与者被随机平均地分配到两个组。使用SPSS软件(19.0版)生成随机数,并由山西省中医院的专业统计人员分配。药物按随机编号进行数字标记和排序。药物随机化由三九医药股份有限公司进行。患者按顺序被分配到干预组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Participants were randomly assigned to two groups on average. Random numbers were generated using SPSS software (version 19.0) and assigned by professional statisticians in Shanxi Provincial Hospital of Traditional Chinese Medicine.Drugs are numerically labeled and sorted by random number.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

临床医生、患者和统计人员对患者的分组和干预措施均不可见。

Blinding:

Double blind

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

向主要研究者申请后可公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Open upon application to the principal investigator

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic acquisition and management system

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-03-06 06:25:14